A Multicenter, Randomized, Open-label Parallel Group Pilot Study to Evaluate Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) plus Standard Medical Treatment (SMT) versus SMT alone in Hospitalized Subjects with COVID-19
Latest Information Update: 14 Apr 2022
At a glance
- Drugs Immune globulin (Primary)
- Indications COVID 2019 infections; SARS-CoV-2 acute respiratory disease
- Focus Therapeutic Use
- Sponsors Grifols
Most Recent Events
- 09 Mar 2021 Status changed from active, no longer recruiting to completed.
- 09 Feb 2021 Status changed from recruiting to active, no longer recruiting.
- 15 Jan 2021 Planned End Date changed from 1 Dec 2020 to 1 Mar 2021.